I haven't even considered that Humanigen would agree to take on Baudax's debt and overhead.
I think management's goal is to help developers provide for a comprehensive cancer treatment line of products derived from state-of-the-art technologies, to include Treg, CAR-T, and Xspray's Hynap technology for CML, to complement our effort with AML. This is already a $2B market for Xspray, and an NDA next year could have added revenue potential, especially if lenz can be effective in enabling nilotinib to cease incurring food interactions, and eliminate the black box warning on their packaging. Lenz could be the "go-to" product for developers bringing these new platforms and therapeutics to market.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.